Breaking down findings of new study on weight loss drugs and breast cancerBreaking down findings of new study on weight loss drugs and breast cancer
Researchers from Penn Medicine found women taking GLP-1 drugs are less likely to be diagnosed with breast cancer. Dr. Celine Gounder breaks down the study’s findings and if the drugs caused the difference.
Weight-loss drugs can cut breast cancer risk by up to 30%, studies suggestWeight-loss drugs can cut breast cancer risk by up to 30%, studies suggest
Three studies add to evidence that jabs could be part of cancer-fighting toolkit to cut risk of developing or dying from diseaseWeight-loss drugs can cut the risk of developing or dying from cancer by 30%, doctors have said.Millions of people already use the drugs to treat obesity. Now a series of studies presented at the world’s largest oncology conference suggest the drugs could play a role in preventing and treating cancer. Continue reading…
Weight-loss drugs can cut breast cancer risk by up to 30%, studies suggestWeight-loss drugs can cut breast cancer risk by up to 30%, studies suggest
Three studies add to evidence that jabs could be part of cancer-fighting toolkit to cut risk of developing or dying from diseaseWeight-loss drugs can cut the risk of developing or dying from cancer by 30%, doctors have said.Millions of people already use the drugs to treat obesity. Now a series of studies presented at the world’s largest oncology conference suggest the drugs could play a role in preventing and treating cancer. Continue reading…
GLP-1 use linked to lower breast cancer incidence in large cohort studyGLP-1 use linked to lower breast cancer incidence in large cohort study
A retrospective analysis of more than 110,000 women between the ages of 45 and 80 found that those who took GLP-1 medications were about 30% less likely to develop breast cancer than those who did not take GLP-1 medications, according to research presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract Read More
One fat helped pancreatic cancer grow while another cut disease in halfOne fat helped pancreatic cancer grow while another cut disease in half
A surprising new study suggests that when it comes to pancreatic cancer, the kind of fat you eat may matter more than how much. Researchers found that oleic acid—the main fat in olive oil and several other common foods—sped up tumor growth in mice predisposed to pancreatic cancer, while omega-3-rich fats from fish oil dramatically slowed disease development.
One fat helped pancreatic cancer grow while another cut disease in halfOne fat helped pancreatic cancer grow while another cut disease in half
A surprising new study suggests that when it comes to pancreatic cancer, the kind of fat you eat may matter more than how much. Researchers found that oleic acid—the main fat in olive oil and several other common foods—sped up tumor growth in mice predisposed to pancreatic cancer, while omega-3-rich fats from fish oil dramatically slowed disease development.
How digital platforms and policy shifts reshape GLP-1 affordabilityHow digital platforms and policy shifts reshape GLP-1 affordability
A News and Perspectives report on emerging pharmaceutical access models in the United States has been published in the Journal of Medical Internet Research. In “Affordable GLP-1? When Digital Platforms Meet Policy Reform”, a JMIR Correspondent Xiangming Jenny Zhan investigates how a convergence of federal policy, manufacturer-led digital distribution, and telehealth integration has drastically lowered Read More
The Conundrum of Exercise for Weight Management in the GLP-1 Receptor Agonist EraThe Conundrum of Exercise for Weight Management in the GLP-1 Receptor Agonist Era
This Perspective describes the challenges of prescribing exercise for weight loss, with and without the use of glucagon-like peptide 1 (GLP-1) receptor agonists, and discusses strategies clinicians can use to improve adherence to exercise recommendations. This Perspective describes the challenges of prescribing exercise for weight loss, with and without the use of glucagon-like peptide 1 Read More
Can AI beat breast cancer?Can AI beat breast cancer?
An artificial intelligence (AI) system that combines breast cancer tissue images with molecular marker data achieves high accuracy in diagnosis, tumor classification, and survival prediction. Details of the research are reported in the International Journal of Data Mining and Bioinformatics.
PET imaging tracks whole-body metabolic changes after bariatric surgeryPET imaging tracks whole-body metabolic changes after bariatric surgery
A novel PET imaging framework reveals that bariatric surgery impacts not only body weight, but also the metabolic function of multiple organs. These PET-derived insights into organ-level responses to surgery could support more precise treatment monitoring and personalized metabolic care. This research was presented at the Society of Nuclear Medicine and Molecular Imaging 2026 Annual Meeting.